These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24018261)

  • 1. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
    Matsuo M; Cui L; Kim J; Hiramatsu K
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.
    Saito M; Katayama Y; Hishinuma T; Iwamoto A; Aiba Y; Kuwahara-Arai K; Cui L; Matsuo M; Aritaka N; Hiramatsu K
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5024-35. PubMed ID: 24841271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.
    Matsuo M; Hishinuma T; Katayama Y; Cui L; Kapi M; Hiramatsu K
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4188-95. PubMed ID: 21746940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".
    Matsuo M; Hishinuma T; Katayama Y; Hiramatsu K
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4215-25. PubMed ID: 25941225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
    Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
    Katayama Y; Murakami-Kuroda H; Cui L; Hiramatsu K
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3190-6. PubMed ID: 19451283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.
    Cafiso V; Bertuccio T; Spina D; Purrello S; Campanile F; Di Pietro C; Purrello M; Stefani S
    PLoS One; 2012; 7(1):e29573. PubMed ID: 22253738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain.
    Di Gregorio S; Fernandez S; Cuirolo A; Verlaine O; Amoroso A; Mengin-Lecreulx D; Famiglietti A; Joris B; Mollerach M
    Microb Drug Resist; 2017 Jan; 23(1):44-50. PubMed ID: 27991847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staphylococcus aureus response and adaptation to vancomycin.
    Fait A; Silva SF; Abrahamsson JÅH; Ingmer H
    Adv Microb Physiol; 2024; 85():201-258. PubMed ID: 39059821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
    Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
    BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
    Shoji M; Cui L; Iizuka R; Komoto A; Neoh HM; Watanabe Y; Hishinuma T; Hiramatsu K
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3870-81. PubMed ID: 21628539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing.
    Chen CJ; Lin MH; Shu JC; Lu JJ
    J Antimicrob Chemother; 2014 Feb; 69(2):349-54. PubMed ID: 24092658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.
    Katayama Y; Azechi T; Miyazaki M; Takata T; Sekine M; Matsui H; Hanaki H; Yahara K; Sasano H; Asakura K; Takaku T; Ochiai T; Komatsu N; Chambers HF
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
    Neoh HM; Cui L; Yuzawa H; Takeuchi F; Matsuo M; Hiramatsu K
    Antimicrob Agents Chemother; 2008 Jan; 52(1):45-53. PubMed ID: 17954695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.
    Howden BP; Peleg AY; Stinear TP
    Infect Genet Evol; 2014 Jan; 21():575-82. PubMed ID: 23567819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VraR Binding to the Promoter Region of
    Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile - area under curve (PAP-AUC).
    Silveira ACO; Caierão J; Silva CI; Anzai EK; McCulloch JA; d'Azevedo PA; Sincero TCM
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114854. PubMed ID: 31366440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
    Zhang S; Sun X; Chang W; Dai Y; Ma X
    PLoS One; 2015; 10(8):e0136082. PubMed ID: 26287490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.